Skip to main content
Clinical Trials/NCT06105294
NCT06105294
Terminated
Not Applicable

Time-Restricted Eating as an Adjunctive Intervention for Bipolar Disorder: Acceptability and Feasibility

University of California, Berkeley1 site in 1 country1 target enrollmentJune 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Bipolar Disorder
Sponsor
University of California, Berkeley
Enrollment
1
Locations
1
Primary Endpoint
Acceptability as assessed using self-ratings on items designed for this study
Status
Terminated
Last Updated
2 years ago

Overview

Brief Summary

This is a pilot trial to examine the acceptability and feasibility of time-restricted eating as an adjunct to medication treatment for bipolar disorder.

Detailed Description

Time-restricted eating (TRE) is a way of scheduling food intake that has been shown to improve circadian rhythms in animals and humans. TRE is based on animal and human science that shows that the timing of eating powerfully influences diurnal rhythms. Animal research has shown that feeding during sleep periods leads to a surge of norepinephrine, cortisol, wakefulness, and activity. Drawing on this, over a decade of studies have examined the impact of experimentally randomizing mice to time-restricted feeding during wake hours (vs. 24-hour ad libitum feeding). Importantly, caloric intake and other facets of diet were yoked for strict control. A consistent finding is that TRE had powerful benefits for circadian and metabolic indicators across studies,and more recent data also shows benefit for animal longevity. Here, the investigators' goal is to extend this work to bipolar disorder (BD). More specifically, the investigators will gather data to examine the acceptability and feasibility of TRE among those who self-identify with bipolar disorder and who experience some problems with sleep, circadian rhythms, or schedules. The investigators will gather measures of mania, depression, sleep, and QOL, to provide preliminary evidence of change on these dimensions.

Registry
clinicaltrials.gov
Start Date
June 1, 2023
End Date
July 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • adults diagnosed with bipolar disorder and currently receiving medical care for their bipolar disorder.
  • Experiencing schedule/sleep or circadian problem in the past 3 months
  • Medication regimens stable for past month
  • Adequate English language skills for taking part in the program.
  • Living in California.

Exclusion Criteria

  • Cognitive deficits (Screening OMC Test)
  • Current: psychosis, (hypo)mania, major depressive episode, substance/alcohol use disorders, eating disorder diagnoses or acute suicidal risk (MINI interview; see DSM5 TRE screening)
  • High scores (\> 5) on the Screening Eating Disorder Examination Questionnaire
  • Current shift work
  • \>5 kg weight change within 3 months
  • Pregnancy
  • Breastfeeding
  • Uncorrected hypo or hyperthyroidism
  • \* diabetes type 1
  • Gastrointestinal conditions impairing nutrient absorption

Outcomes

Primary Outcomes

Acceptability as assessed using self-ratings on items designed for this study

Time Frame: Immediately post-treatment (10 weeks)

self-ratings of the acceptability of the intervention

Feasibility as assessed by percent of clients who complete the assessments and intervention

Time Frame: Immediately post-treatment (10 weeks)

Percentage of clients who do not drop out of the trial. Drop out would be defined as not completing the TRE intervention, or failing to complete the end-of-treatment intervention.

Secondary Outcomes

  • Lower scores on two Patient Reported Outcome Measurement Information System (PROMIS) sleep scales(Change from baseline to immediately post-treatment (10 weeks))
  • higher scores on Self-rated Quality of Life(Change from baseline to immediatly post-treatment (10 weeks))
  • Lower Mania symptoms as assessed with the Patient Mania Questionnaire-9(Change from baseline to immediately post-treatment (10 weeks))
  • Lower Depression symptoms as assessed with the Patient Health Questionnaire-9(Change from baseline to immediately post-treatment (10 weeks))

Study Sites (1)

Loading locations...

Similar Trials